# Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance

> clinical trial · VERIFIED · 2026-07-22

Status: ACTIVE_NOT_RECRUITING · Sponsor: PharmaEssentia · Condition: Essential Thrombocythemia

- Company: PharmaEssentia
- Sector: Essential Thrombocythemia
- Primary source: https://clinicaltrials.gov/study/NCT04285086

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.